New York, March 15, 2023 - PRISM MarketView - Shares in Madrigal Pharmaceuticals (Nasdaq: MDGL) soared this week after the FDA granted accelerated approved the company’s drug candidate Rezdiffra™ in the treatment of nonalcoholic steatohepatitis (NASH). This represents the first and only drug to be approved for NASH, an advanced liver disease and a leading cause of liver-related mortality, that affects between 1.5% and 6.5% of the US adult population.
Rezdiffra is a once-daily, oral THR-β agonist designed to target key underlying causes of NASH.
“Madrigal would like to thank the many patients who made the accelerated approval of Rezdiffra possible by participating in our clinical studies. We believe Rezdiffra will change the treatment paradigm for NASH with moderate to advanced liver fibrosis, giving physicians a liver-directed therapy to help improve fibrosis and resolve NASH before their patients progress to cirrhosis.”
Becky Taub, M.D., the Founder, Chief Medical Officer and President of Research & Development of Madrigal
Highlights
The accelerated approval of Rezdiffra was based on results from Madrigal’s Phase 3 MAESTRO-NASH trial, an ongoing pivotal, multicenter, randomized, double-blind, placebo-controlled study that enrolled 1,759 patients with biopsy-confirmed NASH. Results of the study were recently published in the New England Journal of Medicine.
The trial demonstrated that 100 mg and 80 mg doses of Rezdiffra demonstrated statistically significant improvement compared to placebo on NASH resolution with no worsening of fibrosis.
Fibrosis improvement and NASH resolution were consistent regardless of age, gender, type 2 diabetes status, or fibrosis stage.
Madrigal estimates that approximately 1.5 million patients have been diagnosed with NASH in the U.S., of which approximately 525,000 have NASH with moderate to advanced liver fibrosis.
About Madrigal Pharmaceuticals
Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) is a biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (NASH), a liver disease with high unmet medical need. Madrigal’s medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-β agonist designed to target key underlying causes of NASH. For more information, visit www.madrigalpharma.com.
About PRISM MarketView:
Established in 2020, PRISM MarketView is dedicated to the monitoring and analysis of small cap stocks in burgeoning sectors. We deliver up-to-the-minute financial market news, provide comprehensive investor tools and foster a dynamic investor community. Central to our offerings are proprietary indexes that observe emerging sectors, including biotech, clean energy, next-generation tech, medical devices and beyond. Visit us at prismmarketview.com and follow us on Twitter.
Disclaimer:
PRISM MarketView is not a registered or licensed broker-dealer or investment adviser and does not offer investment advice. The information provided in this communication is not intended to constitute an offer to sell, a solicitation of an offer to buy, or a recommendation for any security.
Contact:
Prism MarketView | Stock Market News & Investment Opportunities
PRISM MarketView - Social Media (X)